# Beta 3 Agonist Treatment in Heart Failure-2

> **NCT03926754** · PHASE2,PHASE3 · COMPLETED · sponsor: **Henning Bundgaard** · enrollment: 56 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction NYHA Class III-IV

## Interventions

- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT03926754
- **Lead sponsor:** Henning Bundgaard
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-23
- **Primary completion:** 2021-01-21
- **Final completion:** 2021-01-21
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926754, "Beta 3 Agonist Treatment in Heart Failure-2". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03926754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*